article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations.

article thumbnail

It Finally Happened – FDA’s OPDP Issues First Letter of 2023

Eye on FDA

The label for the medicine includes a boxed warning regarding potential issues related to complications for the liver (toxicity) and heart (QT prolongation). It was the second letter for this company, the first having been issued in August, 2020 for a TV advertisement. Of those without boxed warnings (9 in number), only 2 had Warning Letters.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

The issues are holding up discussions between the agency and company about labeling and post-marketing requirements for teplizumab, and are concentrated around the pharmacokinetics data for the antibody, and whether it is comparable to the drug that its original developer Eli Lilly entered into clinical trials.

article thumbnail

Sanofi extends its Pompe range with first Nexviazyme OK

pharmaphorum

In 2010, Lumizyme’s label was expanded to the under-right group as well. Myozyme was first to market in 2006 for infantile-onset Pompe, with Lumizyme reaching the market four years later to treat late-onset Pompe in children aged over eight.

article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

Based on fluorescently labelled antibodies and drugs, the technology offers an array of benefits to drug discovery, from characterising complex cell models of disease to understanding the molecular mechanism of drug action. J Cell Sci (2010) 123 (8): 1183–1189. Figure 2 ). Ex vivo tissue analysis. J Multidiscip Healthc. Gunnarsson, A.,

Labelling 105
article thumbnail

High risk, high reward – the future of CAR-T therapy in CLL

Pharmaceutical Technology

In 2010, two patients with end-stage refractory chronic lymphocytic leukaemia (CLL) were administered Novartis’ autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah (tisagenlecleucel), as part of a Phase I trial.

article thumbnail

Shining a light on Raman for microbiological analysis

European Pharmaceutical Review

11 Future methods are likely to require samples being collected, labelled, filtered and processed to obtain their spectra. Adv Appl Microbiol 2010; 70:153–186 Teng L, et al. Label-free, rapid and quantitative phenotyping of stress response in E. Eng Life Sci; 2010; 10:422–429 De Marchi S, et al. link] Huang WE, et al.

Labelling 121